Results 201 to 210 of about 125,713 (396)
Abstract Machine‐learning (ML) models in flow cytometry have the potential to reduce error rates, increase reproducibility, and boost the efficiency of clinical labs. While numerous ML models for flow cytometry data have been proposed, few studies have described the clinical deployment of such models.
Lauren M. Zuromski+10 more
wiley +1 more source
Serial monitoring of BCR–ABL by peripheral blood real‐time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia [PDF]
Lihui Wang+4 more
openalex +1 more source
Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids [PDF]
Valentina Rapozzi
openalex +1 more source
RORγt‐APCs: The New Masters of Oral Tolerance
ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley +1 more source
Deletion of sequences flanking the t(9;22) breakpoint: a secondary genetic event associated with loss of cytogenetic response to interferon in a Philadelphia‐positive chronic myeloid leukaemia patient [PDF]
Eva Arranz+7 more
openalex +1 more source
Cancer patients presenting to the emergency department ED with dyspnoea. Among 2153 patients presenting to the ED with dyspnea, 473 (22.0%) had an active or past cancer. Acute heart failure (AHF) was the most common final diagnosis in both groups. Pneumonia and cancer‐related dyspnoea were more common in cancer patients.
Paolo Bima+20 more
wiley +1 more source
Do persons with chronic myeloid leukaemia have normal or near normal survival?
T. Radivoyevitch+7 more
semanticscholar +1 more source
Prognostic scoring systems in chronic myeloid leukaemia. [PDF]
Lauseker M, Hoffmann VS, Pfirrmann M.
europepmc +1 more source